BioSpace News Archive

First published comparative data for key second-line (2L) advanced hepatocellular carcinoma (aHCC) treatments using a matching-adjusted indirect comparison (MAIC)

ProMIS Neurosciences, Inc. announced that, in addition to its ongoing program to develop a high-throughput and accurate test for detection of antibodies to the causative agent of COVID-19, it has expanded its collaboration with BC Neuroimmunology to include development of highly sensitive and specific assays to support accurate screening and diagnosis of Alzheimer’s disease.

Bellerophon Therapeutics, Inc. announced the pricing of offerings for an aggregate of 3,076,923 shares of its common stock at a public offering price of $13.00 per share.

ArcherDX, Inc. announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation for its next-generation sequencing device under development as a companion diagnostic to detect neurotrophic receptor tyrosine kinase gene fusions that lead to the formation and growth of cancer.

Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, announced the publication of an intended use survey for DecisionDx®-SCC, its prognostic test for patients diagnosed with high-risk cutaneous squamous cell carcinoma.

Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced that it has appointed Douglas E. Feltner, M.D. as its Chief Medical Officer effective May 18th, 2020.

On 19 May 2020, Orexo AB held an extraordinary general meeting. The extraordinary general meeting passed the following resolutions.

Biodesix, Inc., a leading diagnostic company in lung disease, announced that it has collaborated with Bio-Rad Laboratories, Inc. to launch a blood-based immunoassay-based test that identifies antibodies to SARS-CoV-2, the virus that causes COVID-19.

Phlow, a U.S.-based, public benefit drug manufacturing corporation, has received federal government funding of $354 million for advanced manufacturing of America’s most essential medicines at risk of shortage, including medicines for the COVID-19 pandemic response.

Experiment supports Brilacidin’s therapeutic potential as a COVID-19 treatment and as a prophylactic agent against COVID-19